Yamamoto Masanori, Watanabe Yusuke, Tada Norio, Naganuma Toru, Araki Motoharu, Yamanaka Futoshi, Mizutani Kazuki, Tabata Minoru, Ueno Hiroshi, Takagi Kensuke, Higashimori Akihiro, Shirai Shinichi, Hayashida Kentaro
Department of cardiology, Toyohashi Heart Center, Toyohashi, Japan; Department of cardiology, Nagoya Heart Center, Nagoya, Japan.
Department of cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Cardiovasc Revasc Med. 2019 Oct;20(10):843-851. doi: 10.1016/j.carrev.2018.11.024. Epub 2018 Dec 4.
We aimed to assess real-world clinical outcomes of transcatheter aortic valve replacement (TAVR) in Japan.
Data are limited concerning procedural safety and valve performance following TAVR in Japanese. A program by an on-site proctor and procedure screening system was applied during TAVR introduction.
We consecutively enrolled 1613 patients who underwent TAVR using data from the Optimized CathEter vAlvular iNtervention (OCEAN) Japanese registry, which consists of 14 centers. Baseline characteristics and procedural outcomes including combined early 30-day non-safety, and mortality rates were assessed among 4 groups, divided into quartiles (Q1-Q4).
Most patients were women (70.4%), elderly (84.4 ± 5.1 years), and had a median Society of Thoracic Surgeons score of 6.7(4.7-9.5). The overall 30-day mortality, combined early non-safety, and cumulative 1-year mortality rates were 1.7%, 15.1%, and 11.3%, respectively. Thirty-day mortality was not affected by center experience differences divided into quartiles (1.0%, 2.0%, 2.5%, 1.5%, p = 0.404), whereas 30-day early safety was significantly improved (19.1%, 17.9%, 14.6%, 8.9%, p < 0.001). Thirty-day mortality was 0% under transfemoral on-site proctor. Cox-regression multivariate analysis revealed that male sex, clinical frailty scale, New York Heart Association class, creatinine, albumin, hemoglobin, liver disease, and non-transfemoral approach were independent predictive factors of increased midterm mortality risk.
Owning to the global supporting system in Japan, excellent early and midterm outcomes have been achieved to overcome the learning curve of the newly introduced TAVR procedure.
我们旨在评估日本经导管主动脉瓣置换术(TAVR)的真实世界临床结局。
关于日本TAVR术后的手术安全性和瓣膜性能的数据有限。在引入TAVR期间应用了现场指导医师计划和手术筛查系统。
我们使用来自优化导管瓣膜介入(OCEAN)日本注册研究的数据,连续纳入了1613例行TAVR的患者,该注册研究由14个中心组成。在分为四分位数(Q1-Q4)的4组中评估基线特征和手术结局,包括早期30天综合非安全性和死亡率。
大多数患者为女性(70.4%),老年患者(84.4±5.1岁),胸外科医师协会评分中位数为6.7(4.7-9.5)。总体30天死亡率、早期综合非安全性和1年累积死亡率分别为1.7%、15.1%和11.3%。四分位数分组的中心经验差异未影响30天死亡率(1.0%、2.0%、2.5%、1.5%,p=0.404),而30天早期安全性显著改善(19.1%、17.9%、14.6%、8.9%,p<0.001)。经股动脉现场指导医师操作下30天死亡率为0%。Cox回归多因素分析显示,男性、临床衰弱量表、纽约心脏协会分级、肌酐、白蛋白、血红蛋白、肝脏疾病和非经股动脉入路是中期死亡风险增加的独立预测因素。
由于日本的全球支持系统,在克服新引入的TAVR手术学习曲线方面已取得了出色的早期和中期结局。